Symbiotec Pharmalab Listing Preview: Shares Debut Tomorrow After 75.08x Subscription, QIB Demand Tops 181x
- August 31, 2026
- Posted by: Neeraj Pandey
- Category: IPO
Symbiotec Pharmalab lists on NSE, BSE tomorrow, Sep 1, 2026. Final subscription 75.08x: QIB 181.20x, NII 77.56x, retail 13.69x. Allotment finalized Aug 28.
Quick Answer
Symbiotec Pharmalab shares are scheduled to list on the NSE and BSE tomorrow, September 1, 2026, after the Rs 1,757 crore initial public offering closed with a final subscription of 75.08 times. The qualified institutional buyer (QIB) category led demand at 181.20 times, followed by non-institutional investors at 77.56 times and retail investors at 13.69 times.
Symbiotec Pharmalab Limited’s shares are scheduled to list on the NSE and BSE tomorrow, September 1, 2026, following the close of its Rs 1,757 crore initial public offering on August 27, 2026. The issue received a final overall subscription of 75.08 times, with the qualified institutional buyer (QIB) category recording the strongest demand at 181.20 times, followed by non-institutional investors at 77.56 times and retail investors at 13.69 times.
The basis of allotment was finalised on August 28, 2026, with shares credited to successful applicants’ demat accounts by August 31, 2026, ahead of tomorrow’s listing.
Click Here – Get Free Investment Predictions
About Symbiotec Pharmalab
Track Symbiotec Pharmalab’s live price once it lists on the Univest Screener
Incorporated in 2002, Symbiotec Pharmalab Limited manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, holding a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs as of FY26. The company’s Rau and Pithampur facilities in Madhya Pradesh are approved by the US FDA, WHO-GMP, and EU-GMP, serving more than 50 domestic and 150 export customers across North America, Europe, and Asia.
Symbiotec Pharmalab IPO: Final Details
| Parameter | Details |
|---|---|
| IPO Dates | August 24 to August 27, 2026 |
| Price Band | Rs 938 to Rs 988 per share |
| Total Issue Size | Rs 1,757 crore |
| Final Overall Subscription | 75.08x |
| QIB Subscription | 181.20x |
| NII Subscription | 77.56x |
| Retail Subscription | 13.69x |
| Allotment Date | August 28, 2026 |
| Demat Credit Date | August 31, 2026 |
| Listing Date | September 1, 2026 (tomorrow) |
| Listing Exchanges | NSE and BSE |
Symbiotec Pharmalab Financial Performance
Symbiotec Pharmalab’s Total Income for FY26 was Rs 872.26 crore, up from Rs 755.98 crore in FY25, with Profit After Tax of Rs 109.90 crore for FY26, compared to Rs 96.79 crore in FY25. EBITDA for FY26 stood at Rs 231.97 crore, reflecting steady margin improvement over recent fiscal years.
What to Expect on Listing Day
With the issue subscribed over 75 times overall and QIB demand exceeding 180 times, market attention will centre on how the stock performs relative to its Rs 988 issue price when trading begins tomorrow. Listing day price discovery reflects real-time market sentiment and can differ meaningfully from pre-listing expectations, so investors who received an allotment should evaluate the company’s long-term fundamentals rather than relying solely on the strength of the subscription figures when deciding whether to hold or sell on listing day.
Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified, or endorsed by SEBI, NSE, or BSE, can vary widely between trackers, and is not always accurate. Investors interested in checking informally reported premium levels may refer to independent trackers such as InvestorGain.com or Chittorgarh.com, treating this data as supplementary only.
Conclusion
Symbiotec Pharmalab’s strong final subscription of 75.08 times, led by overwhelming QIB demand, sets the stage for its market debut tomorrow, September 1, 2026. Investors should track the stock’s opening trade on the NSE and BSE and assess the company’s pharmaceutical business fundamentals for any post-listing investment decisions. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Symbiotec Pharmalab’s listing-day performance.
FAQs on Symbiotec Pharmalab Listing
When does Symbiotec Pharmalab list on the stock exchange?
Ans. Symbiotec Pharmalab shares are scheduled to list on the NSE and BSE tomorrow, September 1, 2026.
What was the final subscription for the Symbiotec Pharmalab IPO?
Ans. The Symbiotec Pharmalab initial public offering closed with a final overall subscription of 75.08 times, with QIB demand at 181.20 times, NII at 77.56 times, and retail at 13.69 times.
When was the Symbiotec Pharmalab IPO allotment finalised?
Ans. The basis of allotment for Symbiotec Pharmalab was finalised on August 28, 2026, with shares credited to successful applicants’ demat accounts by August 31, 2026.
What does Symbiotec Pharmalab manufacture?
Ans. Symbiotec Pharmalab manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, holding a global leadership position in corticosteroid and steroidal-hormone APIs.
What is Symbiotec Pharmalab’s financial performance?
Ans. Symbiotec Pharmalab reported Total Income of Rs 872.26 crore and Profit After Tax of Rs 109.90 crore for FY26, up from Rs 755.98 crore and Rs 96.79 crore respectively in FY25.
Should I buy Symbiotec Pharmalab shares on listing day?
Ans. Whether to hold or sell on listing day depends on individual risk tolerance and the company’s long-term fundamentals, rather than the subscription figures alone. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decision.
